Related Experiment Video
Updated: Mar 17, 2026
08:17
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
11.6K
Triple inhaled therapy for chronic obstructive pulmonary disease
Paolo Montuschi1, Mario Malerba2, Giuseppe Macis3
1Department of Pharmacology, Faculty of Medicine, University Hospital Agostino Gemelli, Catholic University of the Sacred Heart, Rome, Italy.
Drug Discovery Today
|July 26, 2016
Summary
Triple inhaled therapy combining long-acting muscarinic receptor antagonist (LAMA) with inhaled corticosteroid (ICS)/long-acting β2-adrenoceptor agonist (LABA) fixed-dose combinations (FDCs) shows promise for improving COPD treatment, especially in severe cases.
Area of Science:
- Pulmonology
- Pharmacology
- Respiratory Medicine
Background:
- Triple therapy, combining long-acting muscarinic receptor antagonist (LAMA) with inhaled corticosteroid (ICS)/long-acting β2-adrenoceptor agonist (LABA) fixed-dose combinations (FDCs), offers convenient drug delivery for chronic obstructive pulmonary disease (COPD).
- Adding a LAMA to existing ICS/LABA FDCs can enhance the efficacy of pharmacological treatment for COPD patients.
Purpose of the Study:
- To review the development and potential utility of novel inhaled ICS/LABA/LAMA FDCs for COPD management.
- To identify specific COPD patient phenotypes that may benefit most from triple inhaled therapy.
Main Methods:
- Review of clinical development status for new ICS/LABA/LAMA FDCs.
- Analysis of potential benefits in severe COPD, including those with eosinophilia, asthma-COPD overlap syndrome (ACOS), or frequent exacerbations.
Main Results:
- Several new inhaled ICS/LABA/LAMA FDCs are in Phase III clinical development.
- Triple inhaled therapy is suggested as particularly beneficial for severe to very severe COPD patients, especially those with specific biomarkers or clinical characteristics.
Conclusions:
- New triple inhaled therapies offer a convenient and potentially more effective treatment option for COPD.
- Further prospective studies are needed to confirm the efficacy and safety of triple ICS/LABA/LAMA therapy in defined COPD phenotypes.
More Related Videos
Related Concept Videos
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.3K
01:23Inhaled Medications
960
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
960
01:26COPD: Management Using Bronchodilators and Corticosteroids
1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
4.1K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
4.1K
01:24Chronic Obstructive Pulmonary Disease
3.0K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
3.0K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
4.0K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
4.0K